Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Lancet
; 391(10126): 1163-1173, 2018 03 24.
Article
in En
| MEDLINE
| ID: mdl-29433850
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Phenylurea Compounds
/
Quinolines
/
Niacinamide
/
Carcinoma, Hepatocellular
/
Liver Neoplasms
/
Antineoplastic Agents
Type of study:
Clinical_trials
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Lancet
Year:
2018
Type:
Article